Attached files
file | filename |
---|---|
8-K - FORM 8-K - Protalix BioTherapeutics, Inc. | y04727e8vk.htm |
Exhibit 99.1
Protalix Biotherapeutics to Present at the Tel Aviv Stock Exchange 100 Investment Conference
CARMIEL, Israel, April 7, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX,
TASE:PLX), announced today that Yossi Maimon, the Companys Chief Financial Officer, will present
at the Tel Aviv Stock Exchange 100 investment conference on Tuesday, April 12, 2011 at the Hilton
Tel Aviv in Israel.
The Tel Aviv Stock Exchange 100 investment conference provides TA-100 index listed companies with
the opportunity to present to institutional and private investors. The conference will have three
sessions running in parallel: financial and industrial, real estate and retail, and technology and
communications.
About Protalix
Protalix is a biopharmaceutical company focused on the development and commercialization of
recombinant therapeutic proteins expressed through its proprietary plant cell based expression
system, ProCellEx. Protalixs unique expression system presents a proprietary method for
developing recombinant proteins in a cost-effective, industrial-scale manner in an environment free
of mammalian components and viruses. Protalixs lead compound taliglucerase alfa, an enzyme
replacement therapy for the treatment of Gaucher disease, completed Phase III development. To
date, marketing applications have been submitted for taliglucerase alfa in the United States,
European Union, Brazil and Israel. Protalixs development pipeline also includes: PRX-105, a
pegylated recombinant human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment
program; PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment
of Fabry disease; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot
cells, also for the treatment of Gaucher disease; and pr-antiTNF, a biosimilar version of
etanercept (Enbrel) for the treatment of rheumatoid arthritis.
Forward Looking Statements
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual future experience and results to differ
materially from the statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve a high degree of
risk. Factors that might cause material differences include, among others, risks relating to: the
successful preclinical development of our product candidates; the completion of our clinical
trials; the review process of the U.S. Food and Drug Administration, or FDA, the European Medicines
Agency, or EMEA, other foreign regulatory bodies and other governmental regulatory bodies; delays
in the FDAs, the EMEAs or other health regulatory authorities approval of any applications we
file or refusals to approve such filings; the risk that the FDA may find that the information we
provide in a resubmission of the NDA for taliglucerase alfa in response
to our receipt of a complete response letter from the FDA in February 2011 is insufficient for
regulatory approval; and other factors described in our filings with the Securities and Exchange
Commission. Companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial
results or in preliminary findings for such clinical trials. Failure to obtain approval from the
FDA, EMEA or any other foreign regulatory authority of any of our drug candidates in a timely
manner, if at all, will severely undermine our business and results of operations by reducing our
potential marketable products and our ability to generate corresponding product revenues. The
statements in this release are valid only as of the date hereof and we disclaim any obligation to
update this information.
Investor Contact
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com